Validation of the international tumor budding consensus conference (ITBCC 2016) recommendations on tumor budding in stage I-IV colorectal cancer.

Dawson, Heather; Galuppini, Francesca; Träger, Peter; Berger, Martin D.; Studer, Peter; Brügger, Lukas; Zlobec, Inti; Inderbitzin, Daniel; Lugli, Alessandro (2019). Validation of the international tumor budding consensus conference (ITBCC 2016) recommendations on tumor budding in stage I-IV colorectal cancer. Human pathology, 85, pp. 145-151. Elsevier 10.1016/j.humpath.2018.10.023

[img] Text
1-s2.0-S0046817718304209-main.pdf - Accepted Version
Restricted to registered users only until 12 November 2019.
Available under License Publisher holds Copyright.

Download (3MB) | Request a copy

Tumor budding is a robust prognostic parameter in colorectal cancer and can be used as an additional factor to guide patient management. Though backed by large bodies of data, a standardized scoring method is essential for integrating tumor budding in reporting protocols. The International Tumor Budding Consensus Conference (ITBCC) 2016 has proposed such a scoring system. The aim of this study is to validate the ITBCC method of tumor budding assessment on a well-characterized CRC cohort. 379 patients with resected Stage I-IV colorectal cancer were entered into the study. Tumor budding was scored by two pathologists according to the ITBCC recommendations on hematoxylin and eosin-stained slides and scored as BD1 (low-), BD2 (intermediate-) and BD3 (high-grade). Analysis was performed using a 3-tier approach, a 2-tier approach (BD1+2 versus BD3) and budding as a continuous variable. High-grade tumor budding was associated with adverse clinicopathological features including higher pT, higher pN stage and higher TNM stage (all P<.001) and poorer overall survival on univariate analysis (P=.0251 for BD1/2/3, P=.0106 for BD1+2 versus BD3 and P=.0195 for continuous scores (HR 1.023 (95%CI: 1.004-1.043 per bud)). In stage II cancers, BD3 was associated with poorer disease-free survival (P<.01). Tumor budding assessed by the method proposed by the ITBCC is applicable to colorectal cancer resection specimens and can be used for widespread reporting in routine.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DBMR Forschung Mu35 > Forschungsgruppe Viszeralchirurgie
04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DBMR Forschung Mu35 > Forschungsgruppe Viszeralchirurgie

04 Faculty of Medicine > Department of Gastro-intestinal, Liver and Lung Disorders (DMLL) > Clinic of Visceral Surgery and Medicine > Visceral Surgery
04 Faculty of Medicine > Service Sector > Institute of Pathology
04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology

UniBE Contributor:

Dawson, Heather; Berger, Martin Dave; Studer, Peter; Brügger, Lukas; Zlobec, Inti; Inderbitzin, Daniel and Lugli, Alessandro

Subjects:

500 Science > 570 Life sciences; biology
600 Technology > 610 Medicine & health

ISSN:

0046-8177

Publisher:

Elsevier

Language:

English

Submitter:

Alessandro Lugli

Date Deposited:

28 Nov 2018 15:00

Last Modified:

12 Apr 2019 01:31

Publisher DOI:

10.1016/j.humpath.2018.10.023

PubMed ID:

30428391

Uncontrolled Keywords:

Colorectal Cancer Consensus Conference Tumor Budding

BORIS DOI:

10.7892/boris.121733

URI:

https://boris.unibe.ch/id/eprint/121733

Actions (login required)

Edit item Edit item
Provide Feedback